margetuximab

Phase 3Monoclonal antibody

TTerSera Therapeutics LLC

margetuximab is one of 24 biologic programs targeting Metastatic Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic NeoplasmActive, not recruiting

Breast CancerActive, not recruiting

Metastatic NeoplasmPhase 1

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

margetuximab

TTerSera Therapeutics LLC

Phase 3

3 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Adenocard

Astellas

Preclinical

1 6

Lexiscan

Astellas

Preclinical

1 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Study completion

NCT04425018

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Completed·MMacroGenics·Phase 3·NCT02492711·624 enrolled

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Withdrawn·MMedSIR·Phase 2·NCT05227131

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Completed·MMacroGenics·Phase 2·NCT01828021·25 enrolled

Chemotherapy1 trial

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Completed·MMacroGenics·Phase 2/3·NCT04082364·82 enrolled

Metastatic Neoplasm1 trial

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Completed·MMacroGenics·Phase 1·NCT03219268·277 enrolled

ESS1 trial

Margetuximab Expanded Access Program

Approved for marketing·TTerSera Therapeutics LLC··NCT03133988

Efficacy and Safety1 trial

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Unknown status·ZZai Lab (Shanghai) Co., Ltd.·Phase 2·NCT04262804·123 enrolled

3 more indications

HER2 Positive1 trial

Safety Study of MGAH22 in HER2-positive Carcinomas

Completed·MMacroGenics·Phase 1·NCT01148849·66 enrolled

Gastroesophageal Junction Cancer1 trial

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Completed·MMacroGenics·Phase 1/2·NCT02689284·95 enrolled

Unspecified1 trial

MARGetuximab Or Trastuzumab (MARGOT)

Active, not recruiting·—·Phase 2·NCT04425018·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for margetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — margetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for margetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TerSera Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: TTerSera Therapeutics LLC

margetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer3 trials

Chemotherapy1 trial

Metastatic Neoplasm1 trial

ESS1 trial

Efficacy and Safety1 trial

HER2 Positive1 trial

Gastroesophageal Junction Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News